Oppenheimer Reiterates Outperform Rating on Cognition Therapeutics (CGTX)

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $9.00 price target on Cognition Therapeutics (NASDAQ: CGTX).

The analyst commented ,"CGTX hosted a KOL event on the prevailing unmet need for treatment in AD and pharmacological rationale of CT1812 with leading physicians Dr. Anton Porsteinsson, Dr. Martin Sadowski, and Dr. Jort Vijverberg. Experts discussed the importance of biomarkers, such as the encouraging EEG data from Ph1/2 SEQUEL study, as well as synaptic biomarkers and neuroimaging that we believe should elucidate CT1812's differentiated MOA as a σ-2 receptor modulator. We also see several potential advantages for CT1812 compared to Aβ mAbs, such as addressing a broader patient population, and synergies in combination regimens. Ph2 SHINE in mild/moderate AD completed enrollment, and CGTX expects topline results in mid-2024 followed by full results likely at AAIC. We see significant upside potential with the upcoming catalysts."

For an analyst ratings summary and ratings history on Cognition Therapeutics click here. For more ratings news on Cognition Therapeutics click here.

Shares of Cognition Therapeutics closed at $1.91 yesterday.

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
• Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
• Kotak Upgrades Max Financial Services (MAXF:IN) to Buy (1)